Ezmekly vs Mektovi: Side-by-Side Comparison
Quick answer: Ezmekly and Mektovi are both mek inhibitor used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Ezmekly | Mektovi |
|---|---|---|
| Drug class | MEK inhibitor | MEK inhibitor |
| ATC code | L01EE | L01EE03 |
| Primary indications | Neurofibromatosis type 1 with plexiform neurofibromas | Metastatic melanoma with BRAF V600 mutation, BRAF-mutant colorectal cancer |
| Mechanism | Mirdametinib is a small-molecule inhibitor of MEK1/MEK2 in the RAS/MAPK pathway | Selective MEK1/2 inhibitor used in combination with encorafenib to block MAPK pathway in BRAF-mutant cancers |
| Common dose | 2 mg/m² twice daily (max 4 mg BID) | 45 mg orally twice daily |
| Detail page | Ezmekly details → | Mektovi details → |
How to choose between Ezmekly and Mektovi
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All MEK inhibitor on iMedic · Ezmekly full details · Mektovi full details
Frequently asked questions
Is Ezmekly better than Mektovi?
Neither is universally 'better.' They are both mek inhibitor with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Ezmekly to Mektovi?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Ezmekly and Mektovi have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Ezmekly and Mektovi available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.